2104. Susceptibility Trends in Antifungal Resistance (STAR) Study: Preliminary Data from A New Prospective Antifungal Surveillance Study

Abstract

Background

The development of new anti-infectives has increased rapidly over the past ten years. The need to support these important, life-saving products has increased as well. The STAR program was developed in 2018 to provide a repository of recent clinical fungal isolates with known susceptibility profiles and to monitor resistance trends over time. STAR reports the susceptibility patterns of the earliest STAR data concerning echinocandins, second-generation triazoles, and fluconazole against clinical Candida albicans and non-albicans strains including C. auris from worldwide sources.

Methods

Clinical isolates of Candida spp. (n = 203, from 2017–2018) from culture KOL investigator sites in the United States, Asia and the EU, were tested. Of these, 203 were isolated from blood or body tissues, and the remaining 11 from miscellaneous sources. Species distribution included mainly C. albicans, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis, and the emerging pathogen C. auris. Antifungals tested were amphotericin B (AMB), anidulafungin (ANID), fluconazole (FLU), isavuconazole (ISA), posaconazole (POS), and voriconazole (VOR). All testing was performed according to CLSI M27-A4 methodology.

Results

Overall, MIC₅₀, MIC₉₀, MIC range and percent susceptibility for each drug are listed in Table 1. Our data showed that for ANID, ISA and POS ≥ 93% of isolates were susceptible. While 84 and 88% were susceptible to FLU and VOR, respectively. Moreover, only 78% of isolates were susceptible to AMB. Interestingly, our data show that C. auris isolates were resistant to at least 1 antifungal with 15% of the C. auris strains (n = 40) showing multidrug resistance.

Conclusion

Ongoing antifungal resistance surveillance like STAR is of utmost importance in order to monitor the efficacy of traditional empirical therapy and for the development of novel antifungal agents. This repository and ongoing STAR study will provide a resource to better support the biopharmaceutical industry’s goals to develop new and more potent antifungal agents. STAR will continue to monitor yeasts and will also include more unusual fungi including Mucor, Rhizopus amongst others.

Disclosures

All authors: No reported disclosures.

Session: 242. Antifungals

Saturday, October 5, 2019: 12:15 PM